Peakman, M, Deale, A, Field, R et al. · Clinical immunology and immunopathology · 1997 · DOI
Researchers tested whether immune system changes were linked to ME/CFS symptoms and whether treating ME/CFS would change immune markers. They measured various immune cell types in 43 ME/CFS patients and healthy controls before and after treatment. They found that most immune markers were similar between patients and controls, and improvements in symptoms were not connected to changes in immune cells.
This study directly challenges the theory that immune system dysfunction causes or maintains ME/CFS, which was a prevalent hypothesis in the 1990s. Understanding whether immune abnormalities are relevant to ME/CFS helps researchers focus on more promising biological mechanisms and prevents misdirected treatment efforts. The findings suggest that if immune involvement exists in ME/CFS, it may be more subtle or different than previously believed.
This study does not prove that the immune system plays no role in ME/CFS—it only shows that certain immune cell counts and activation markers were not strongly associated with illness severity or treatment response in this particular sample. The study measures only one timepoint pair (before/after treatment) and cannot establish whether immune dysfunction occurs in subgroups or in response to specific triggers like exertion. Absence of correlation does not rule out causation or involvement through other immune mechanisms not measured.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →